Clinical Trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Study acronym: IDeate-Lung02
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-08-06
notable Trial sites reduced: 232 -> 229 locations 2026-08-06
notable Primary completion pushed: 2027-04-30 -> 2028-01-30 2026-08-06
minor Completion pushed: 2029-02-22 -> 2029-12-01 2026-08-06
Trial Details
NCT Number NCT06203210
Lead Sponsor Daiichi Sankyo
Collaborators: Merck Sharp & Dohme LLC
Conditions Small Cell Lung Cancer
Enrollment 540 participants
Start Date 2024-05-21
Primary Completion 2028-01-30 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06